Quick Answer
Quince Therapeutics, Inc. reported Total Assets of $114.48 million for the year ending 2024.
- Quince Therapeutics, Inc. showed a decrease of -31.8% in Total Assets from 2023 to 2024.
- This data is from Quince Therapeutics, Inc.'s annual report (Form 10-K), filed with the SEC on March 24, 2025.
- XBRL data for this metric is available from 2018 to 2024 (7 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Quarterly values from 10-Q filings: Q1 2019: $70.60 million | Q2 2019: $143.24 million | Q3 2019: $133.41 million | Q1 2020: $231.21 million | Q2 2020: $219.21 million | Q3 2020: $204.66 million | Q1 2021: $174.52 million | Q2 2021: $161.39 million | Q3 2021: $147.42 million | Q1 2022: $116.13 million | Q2 2022: $117.86 million | Q3 2022: $109.78 million | Q1 2023: $93.32 million | Q2 2023: $88.84 million | Q3 2023: $85.39 million | Q1 2024: $159.29 million | Q2 2024: $134.83 million | Q3 2024: $126.52 million | Q4 2024: $114.48 million | Q1 2025: $107.09 million | Q2 2025: $117.21 million | Q3 2025: $109.90 million.
- Over the full 7 years of available data (2018 to 2024), Quince Therapeutics, Inc.'s Total Assets has grown by 57.1%.
- Historical annual values: Fiscal year 2024: $114.48 million | Fiscal year 2023: $167.90 million | Fiscal year 2022: $103.91 million | Fiscal year 2021: $133.23 million | Fiscal year 2020: $189.47 million | Fiscal year 2019: $124.37 million | Fiscal year 2018: $72.88 million.
- Data sourced from SEC EDGAR public filings as of August 5, 2026.
Last verified: